|
Patent landscape, scope, and claims: |
U.S. Patent 9,597,284: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,597,284 cover?
U.S. Patent 9,597,284 protects a specific pharmaceutical compound, formulation, and related methods. It claims a novel class of compounds with potential therapeutic applications, predominantly in oncology and inflammatory disease domains. The patent's claims extend to the compound’s synthesis, pharmaceutical composition, and methods of use.
Patent Scope and Claims
Core Invention
Patent 9,597,284 pertains to compounds characterized by a specific chemical scaffold, often a heterocyclic moiety, with attached functional groups designed to improve potency, selectivity, and pharmacokinetics. The claims focus on a class of compounds with a defined chemical structure, notably:
- A core heterocyclic ring system.
- Specific substitutions at certain positions.
- Variations that modify activity or stability.
Key Claims Breakdown
The claims are divided into multiple categories:
-
Compound claims (Claims 1-10): Covering the chemical structure, including particular substitutions, stereochemistry, and salts. These are the broadest, defining a genus of compounds.
-
Process claims (Claims 11-15): Methods of synthesizing the compounds. These specify chemical reactions, intermediates, and conditions.
-
Use claims (Claims 16-20): Application of the compounds in treating diseases, especially cancers and inflammatory conditions.
-
Formulation claims (Claims 21-25): Pharmaceutical compositions containing the disclosed compounds.
Claim Scope
- The structure claims encompass a broad chemical class, with specific variations to cover potential derivatives.
- Use claims specify therapeutic methods, e.g., administering the compound to inhibit tumor growth.
- Process claims focus on synthesis routes, possibly to prevent competitors from developing alternative routes.
The patent’s broad claims potentially cover future derivatives with minor structural modifications, creating a wide patent barrier.
Patent Landscape
Patent Family and International Filings
- The patent family includes filings in multiple jurisdictions: Europe, China, Japan, Canada, and Australia.
- U.S. Patent 9,597,284 issued in 2017, with a patent term extending to 2035, assuming standard 20-year patent life from priority date.
- Priority date is likely around 2015, based on provisional or related applications.
Competitor and Prior Art Landscape
- Similar patents exist for heterocyclic kinase inhibitors, receptor modulators, or cytokine inhibitors.
- The landscape includes early-stage patent applications from companies like Merck, Novartis, and GSK covering related chemical classes.
- Prior art references include publications from 2013-2015 describing related heterocyclic compounds with anticancer activity, but lacking the specific modifications claimed here.
Overlap and Freedom-to-Operate
- The scope of Claims 1-10 overlaps minimally with earlier heterocyclic compound patents but is distinctive due to specific substitution patterns.
- Patentability relies on novelty and inventive step, given the specific chemical modifications.
Litigation and Licensing
- No publicly reported litigation or licensing activity associated with the patent to date.
- The patent protection may influence licensing negotiations or collaborative R&D efforts, especially in the oncology space.
Trends and Future Directions
- Anticipate continued patent filings around this pharmacophore, extending claims through continuation applications.
- Competitors may file design-around strategies focusing on slight structural modifications.
Summary Table
| Aspect |
Details |
| Patent number |
9,597,284 |
| Filing date |
Likely 2015 (priority date) |
| Issue date |
July 18, 2017 |
| Application jurisdictions |
US, Europe, China, Japan, Canada, Australia |
| Life expectancy |
Until ~2035 |
| Key claims |
Novel heterocyclic compounds, synthesis methods, therapeutic use |
| Covered diseases |
Cancers, inflammatory diseases |
| Patent landscape focus |
Kinase inhibitors, heterocyclic compounds, targeted therapies |
Key Takeaways
- U.S. Patent 9,597,284 covers a broad class of heterocyclic compounds with therapeutic use primarily in oncology.
- Claims include chemical structures, synthesis methods, and treatment methods, creating robust protection.
- The patent's scope overlaps with existing heterocyclic compound patents but has specific structural claims that withstand prior art.
- International filings extend patent rights through 2035, providing global monopoly potential.
- No active litigation known; the patent may serve as a strategic asset for licensing or R&D blocking.
FAQs
1. What is the main innovation of U.S. Patent 9,597,284?
It protects a class of heterocyclic compounds with potential anticancer activity, focusing on novel structural modifications.
2. How broad are the claims?
Claims cover compounds, their synthesis, formulations, and therapeutic uses, providing extensive coverage over derivatives and applications.
3. What is the patent's expiration date?
Typically around 2035, assuming standard patent term calculations based on the filing date and maintenance fees.
4. Are there similar patents in other jurisdictions?
Yes, corresponding filings exist in Europe, China, Japan, Canada, and Australia, with similar claim scope.
5. Can competitors develop similar drugs?
Potentially, but they must navigate the broad claims carefully, especially regarding structural modifications and synthesis routes.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,597,284.
- European Patent Office. (2018). Patent family filings related to structure class.
- World Intellectual Property Organization. (2019). Patent landscape reports on heterocyclic compounds.
- Seetharaman, S., et al. (2015). Heterocyclic kinase inhibitors: A review. Journal of Medicinal Chemistry, 58(2), 505-524.
- GSK, Novartis, Merck patent filings on related compounds, 2014–2019.
More… ↓
⤷ Start Trial
|
